CYP19A1 and breast carcinoma: Interestingly, although glutamine metabolism is independent of estrogen in aromatase inhibitor-resistant breast cancer, the cross-talk between ER and HER2 upregulates the c-MYC pathway and further increases the expression level of GLS, SLC1A5, and glutamine consumption.